GlobeNewswire Inc | Aug 4, 2021 08:00AM EDT

August 04, 2021

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced that Dr. Jeremy Bender, chief executive officer, is scheduled to participate in a panel discussion at the 12th Annual Wedbush PacGrow Healthcare Conference, which is being held virtually from August 10-11, 2021.

Panel Details:Title: Bullseye Targeted Oncology Part 2Date and time: Wednesday, August 11th, 10:20 a.m. ETPresenter: Jeremy Bender, Ph.D., MBA, Day Ones chief executive officerWebcast: https://ir.dayonebio.com/news-and-events/events

To access the live and archived webcasts, visit the News & Eventssection of the Company's website. A replay of the webcast will be available through the Company's website for 30 days thereafter.

About Day One Biopharmaceuticals Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Our name was inspired by the The Day One Talk1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. We aim to re-envision cancer drug development and redefine whats possible for all people living with cancerregardless of agestarting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Companys lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Companys pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco. For more information, please visit www.dayonebio.com.

1Jennifer W. Mack and Holcombe E. Grier; Journal of Clinical Oncology 2004 22:3, 563-566

Contacts:

Media:1ABDan Budwickdan@1abmedia.com

Investors:LifeSci AdvisorsHans Vitzthum617-430-7578hans@lifesciadvisors.com